The Incanthera direct holding must be worth gbp1.5m after todays rise plus 7.3m warrants which can be exercised anytime, so warrants presumably worth another gbp1.25m approx. This is what i call hidden value on the balance sheet. |
Good to see the rise for the LTHs here and the recent punters. It is somewhat ironic that the rise is due to the success of another company…but beggars can’t be choosers. |
Nice and quiet on here at moment, steady as she blows,when will all the Muppets arrive slagging it off lol GLA |
Money moving to APH [LSE] , excellent profitable healthcare company |
Still life in the old dog yet. |
stockriser - the announcement of no further dilution for now was, on the face of it, undoubtedly good news. It calmed market nerves & marked a turning point in share price direction.
That said, past pronouncements - notably from Tim M - have often proved unreliable. Also, any sale of IMM’s Incanthera holding would, in effect, just be dilution by the back door. Hopefully a commercial deal will come along before then to make this option unnecessary. |
...and it's worth reminding ourselves. This isn't a one-trick-pony. Many potential game changers in the pipeline. Multiple shots on goal. |
TI - Totally agree with you, Mcap is ridiculous for this Co., with so much potential and also as you say no further dilution. |
The Co. confirmed no further dilution. For me that calls the bottom. The upside here is huge. |
Many think this may drop back a bit so they can get in lower - Hmmm, not so sure myself.
GLA SR |
Me too, but trying to keep this under the RADAR. |
Good morning
More interest in these today with a decent share price gain.
No new published news though
I hold few. |
Paul Scott effect!!! He's took a punt pos fame |
Shush!Shush! |
Tks SK - Great interview |
nobbygnome - You say IMM looks cheap, is priced to fail and that its holding & warrants in Incanthera could prove a significant asset.
So despite your reservations about any imminent deals to provide upfront cash, do you regard IMM as over or under valued at its current level (post-today's uptick)?
Notwithstanding McCarthy's pre-disposition to - ahem - exaggerate, I view today's RNS as a major positive.
Assuming he doesn't totally go back on his word in a few weeks' time (admittedly a big assumption), surely the major fear that IMM was about to go bust has been dispelled. For now at least. To me, this is now a share to hold & sell closer to (but importantly before!) any trial readout.
Your thoughts? |
End of dilution!
Nothing to see here :-) |
RNS seems to be a balanced view on where the company is and where it could go; a more measured view to the market based on the look forward activity and fiscal position. Regular updates on progress should underpin the view of the RNS and provide confidence on the trajectory outlined in the RNS. |
Avion is investing $25 million in the P3 that is starting this year. That investment alone is worth multiples of the current market cap. |
And I agree Icanthera could be a significant asset…. |
The last upfront was a big fact ZERO so it would be difficult for it to be lower…. |
Nobby, start another Guild lol
Jeez… is that McCarthy still drawing his pension, this one is going nowhere but down, with jittery dead cat bounces |
P.S. They already have two deals, on US rights in Lupuzor with P3 fully funded, and 10% of Incancthera that has a deal with the worlds largest international health and beauty retailer. This is just not factored into the share price. |
Because they will structure the deal differently. On Lupuzor US rights, they focused on royalty rates getting double digit tiered up to 17%. I suspect they will reduce that a little on CIPD to get a bigger up front payment. |
You make some good points S_K but you are definitely over egging the pudding. Pre clinical programs are of little interest to Pharma so don’t expect any upfront if they get a deal there. And why do you think CIDP will get a significant upfront when SLE got zero upfront?
I don’t dispute it looks cheap if they actually achieve some sort of deal but…. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
